Press Releases Celldex Therapeutics, Inc.

Equities

CLDX

US15117B2025

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-14 pm EDT			5-day change	1st Jan Change
34.67 ^USD	-4.83%		-1.73%	-12.58%

Jun. 11	Celldex Therapeutics Insider Sold Shares Worth $1,586,844, According to a Recent SEC Filing	MT
Jun. 11	Celldex Therapeutics Insider Sold Shares Worth $525,873, According to a Recent SEC Filing	MT

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Celldex Therapeutics to Present at Jefferies Healthcare Conference	Jun. 04	AQ
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024	Jun. 02	AQ
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis	May. 15	AQ
Celldex: Q1 Earnings Snapshot	May. 06	AQ
Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update	May. 06	AQ
Celldex Therapeutics : Corporate Presentation	Apr. 17	PU
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria	Apr. 17	AQ
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference	Mar. 08	AQ
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares	Mar. 06	AQ
Celldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference	Mar. 06	AQ
Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference	Mar. 05	AQ
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares	Mar. 05	AQ
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock	Feb. 29	AQ
Celldex Therapeutics Announces Proposed Public Offering of Common Stock	Feb. 28	AQ
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria	Feb. 26	AQ
Celldex: Q4 Earnings Snapshot	Feb. 26	AQ
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update	Feb. 26	AQ
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria	Feb. 24	AQ
Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	Feb. 06	AQ
Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024	Feb. 05	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Celldex Therapeutics, Inc.

Equities

CLDX

US15117B2025

Press Releases

Filters